INTRODUCTION
In the old paradigm of lung cancer treatment, the role of the pathologist was mainly to differentiate small cell carcinoma from non-small cell carcinoma (NSCC) because of the significant difference in treatment strategies between the 2 entities. Further NSCC subtyping was more or less a moot point because non-small cell lung cancer (NSCLC) patients were essentially treated on the basis of their disease stage and performance status, regardless of subtypes. However, the recent implementation of histology-directed therapy in NSCLC has shifted the paradigm. Some novel biological therapies are lineage-oriented (Table 1) . For instance, treatments with bevacizumab and pemetrexed are limited to non-squamous cell carcinoma because of the serious adverse effects and lack of efficacy, respectively, in squamous cell carcinoma. 1, 2 In addition, advances in lung cancer genotyping, including next-generation sequencing, have led to the discovery of multiple oncogenic driver mutations. Although the corresponding targeted agents are clinically available only for advanced lung cancer patients whose tumors harbor epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, or ROS1 rearrangements, multiple other targeted agents are in the pipeline. 3 Because those targetable alterations are predominantly seen in adenocarcinoma or non-squamous cell carcinoma, specimens with the diagnosis of squamous cell carcinoma may not be submitted for molecular testing at this time. 3 Thus, the differentiation of squamous cell carcinoma from adenocarcinoma and NSCC, not otherwise specified (NOS) in cytology and biopsy specimens is of paramount importance. Because approximately 60% of lung cancer patients present at an advanced stage, 4 fine-needle aspiration (FNA) and small biopsy specimens are important samples for diagnosis and histologic subtyping, and predictive biomarker testing, including immunohistochemistry and molecular assays, can also be performed with cell blocks and biopsies with or without cytology smears. Consequently, a section on terminology and criteria for nonresection specimens has been included in the recently updated World Health Organization (WHO) classification of tumors of the lung, which has traditionally focused on resected tumors. 5 Thus, in this commentary, I discuss the nomenclature of FNA and small biopsy specimens, particularly for NSCC, put forth by the WHO classification of tumors of the lung published in 2015. I also touch on relevant points associated with predictive biomarker testing.
TERMINOLOGY AND CRITERIA FOR FNA AND SMALL BIOPSY SPECIMENS
The WHO classifications for tumors of the lung were traditionally based on resected specimens and did not address issues related to small biopsy or cytology specimens. Because of the recent implementation of histology-directed therapy in NSCLC, particularly for advanced-stage tumors, the increasing utilization of small biopsy and cytology specimens has been more recently addressed by the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society. These recommendations address a number of issues in the cytologic diagnosis of lung cancer. 6, 7 Accordingly, the 2015 WHO classification recommends the following diagnostic terms for NSCC in nonresection specimens from patients with the clinical diagnosis of lung cancer with respect to the differentiation between squamous cell carcinoma and adenocarcinoma: squamous cell carcinoma; adenocarcinoma; NSCC, favor squamous cell carcinoma; NSCC, favor adenocarcinoma; NSCC, NOS with morphologic squamous cell and adenocarcinoma patterns both present, possible adenosquamous carcinoma; and NSCC, NOS. Notably, the definitive diagnosis of adenosquamous carcinoma requires a resection specimen that demonstrates each component composing at least 10% of the tumor cells. 5 Now, in 50% to 70% of FNA and/or small biopsy specimens, the differentiation of squamous cell carcinoma versus adenocarcinoma can be made on the basis of cytomorphologic features alone. Those cases are diagnosed as adenocarcinoma, squamous cell carcinoma, or NSCC, NOS with possible adenosquamous cell carcinoma. However, in the remaining 30% to 50% of small specimens, the poorly differentiated nature of the tumor precludes definitive subtyping based on the cytomorphology. In such cases, the application of a minimal panel of immunohistochemistry consisting of thyroid transcription factor 1 (TTF-1) as an adenocarcinoma marker and p40 or p63 as a squamous marker is recommended as the first attempt using a cell block or biopsy because of their high specificities and moderate to high sensitivities for the corresponding subtypes and because of the easier evaluation of nuclear staining versus cytoplasmic staining (Table 2) . Notably, as a squamous marker, p40 is favored over p63 because of its higher specificity, and a mucin stain may be applied along with TTF-1 to support the diagnosis of adenocarcinoma. 5 If the panel fails to subtype the tumor, an additional panel consisting of napsin A (as an adenocarcinoma marker) and cytokeratin 5/6 (as a squamous marker) can be applied. Larger panels are not recommended on account of their low yield and to conserve as much tissue for subsequent molecular testing as possible. 7 Table 2 shows the possible results of the TTF-1 and p40/ p63 immunohistochemistry panel. In brief, any degree of TTF-1 expression, regardless of p40/p63 expression, supports adenocarcinoma differentiation (NSCC, favor adenocarcinoma). Squamous differentiation is considered only when TTF-1 is negative and p40/p63 is diffusely positive (NSCC, favor squamous cell carcinoma). If the tumor exhibits both TTF-1 and p63 expression in the same tumor cells, it is classified as NSCC, favor adenocarcinoma because some degree of p63 expression can be seen in up to one-third of lung adenocarcinomas. 8 In contrast, p40 expression is limited in adenocarcinomas. 9 In adenosquamous carcinoma, TTF-1 and p40/p63 are both positive but in 2 different populations of tumor cells. As for the term NSCC, favor, it emphasizes the poorly differentiated nature of the tumor, but in my opinion, subtypes without the prefix could be used for the diagnosis as long as the results of immunohistochemistry are described in the note.
Finally, approximately 10% of NSCCs are negative for TTF-1 and focally positive or negative for p40/p63. Such tumors are classified as NSCC, NOS and should be submitted for molecular testing. It is important to note, however, that in null-type tumors, the possibility of a nonlung primary and nonepithelial tumor may need to be excluded with a larger immunohistochemistry panel and clinicopathologic correlation. Apart from the differentiation of squamous cell carcinoma from adenocarcinoma, there are a couple of issues in NSCC that I would like to mention. When there is the possibility of neuroendocrine differentiation according to cytomorphology, immunohistochemistry for neuroendocrine markers (synaptophysin, chromogranin, and/or CD56) needs to be performed to confirm the differentiation. In such cases, the recommended terminology is NSCC with neuroendocrine morphology and positive neuroendocrine markers suggestive of large cell neuroendocrine carcinoma, since the particular morphology may not represent the entire tumor. It is important to note that the application of neuroendocrine immunohistochemistry needs to be limited to tumors with neuroendocrine morphology or those with neuroendocrine carcinoma as a differential diagnosis, such as basaloid squamous cell carcinoma, because 10% to 20% of classic squamous cell carcinomas and adenocarcinomas can express neuroendocrine markers. 10 The subclassification of neuroendocrine tumors is beyond the scope of this commentary, but it is worth emphasizing that a Ki-67 labeling index may be useful when crush artifacts and so forth hamper the evaluation of cytomorphology and mitoses for the differentiation of carcinoids, large cell neuroendocrine carcinomas, and small cell carcinomas.
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Another issue occurs when the tumor exhibits a spindle and/or giant cell morphology. If neoplastic spindle and/or giant cells are seen along with morphologic squamous cell carcinoma or adenocarcinoma, their presence could be indicated in the diagnosis or notes because the diagnosis of pleomorphic, spindle cell, or giant cell carcinoma requires a resection specimen showing that 10% or more of the tumor cells exhibit the corresponding morphology. 5 When FNA and/or biopsy specimens consist solely of spindle and/or giant cells, it is important to differentiate NSCCs from nonepithelial tumors with a immunohistochemistry panel including keratin.
ADENOCARCINOMA SUBTYPES
The 2015 WHO classification includes a number of significant changes from the 2004 system. The discontinuation of the diagnosis of bronchioloalveolar carcinoma is important: the category became obscure and less useful because it was inconsistently used to cover a number of disparate situations. Instead, the term lepidic pattern has been adopted to describe the growth of malignant cells replacing alveolar lining epithelium without stromal invasion. 5 It is well known that the majority of lung adenocarcinomas are morphologically heterogeneous, and if studied closely, more than 90% of tumors will fall into the mixed-subtype 7 Instead, it recognizes 5 histologic patterns (lepidic, papillary, acinar, micropapillary, and solid) and 4 variants (invasive mucinous adenocarcinoma, colloid adenocarcinoma, enteric adenocarcinoma, and fetal adenocarcinoma) in lung adenocarcinomas and recommends that the fraction of each pattern/variant present in the tumor be described with 5% increments and that the predominant pattern be indicated in the final diagnosis. 5 Notably, if the tumor is <3 cm in its greatest dimension and consists solely of a lepidic pattern, it is classified as adenocarcinoma in situ (AIS). If a small tumor predominantly exhibits a lepidic pattern with <0.5-cm invasion (nonlepidic patterns), it is classified as minimally invasive adenocarcinoma (MIA). The presence of pleural, lymphatic, blood vessel, and/or airspace invasion, necrosis, and/or spread through air spaces excludes the diagnosis of MIA. The predominant pattern-based adenocarcinoma classification, including AIS and MIA, has been useful in predicting recurrence-free survival after the resection of early-stage tumors, responses to adjuvant therapy, and molecular alterations; however, there have been only limited studies of the clinical implications of the pattern classification in advanced-stage lung adenocarcinomas. [12] [13] [14] In cytology smears and small biopsies, those patterns may be identified, but it is not practical to classify the tumor on the basis of the predominant pattern in such samples because the tissue sample may not be representative of the entire tumor on account of tumor heterogeneity. In addition, although there are patterns that have been associated with specific molecular alterations, such as papillary and/or lepidic predominant patterns with EGFR mutations, 15 clinicopathologic variables, including the predominant pattern, do not sufficiently predict the presence of genetic alterations. 15, 16 This indicates that all adenocarcinoma samples (and NSCC, NOS samples) from advanced lung cancer patients need to be submitted for molecular testing. Thus, there is no need to specify the predominant pattern in small biopsy or cytology samples. Instead, all patterns present in a specimen may be described along with the diagnosis of adenocarcinoma. Notably, solid patterns with signet ring cells and mucinous cribriform patterns, which have been reported in association with ALK and ROS1 rearrangements, are unusual cytomorphologies for lung adenocarcinoma. [16] [17] [18] Thus, immunohistochemistry for TTF-1 (and/or napsin A) may be warranted to confirm the lung origin, and the presence of such cytomorphologic features is worth mentioning in the note. When only a lepidic pattern is identified in small biopsies, particularly those from early-stage tumors, it raises the possibility of AIS or MIA. The diagnosis of AIS, however, requires a resection specimen exhibiting only a lepidic pattern, and similarly, various features need to be excluded for the diagnosis of MIA. Thus, the possibly of AIS or MIA may only be suggested in the note.
ADDITIONAL NOTE FOR PREDICTIVE BIOMARKER TESTING
As mentioned before, EGFR inhibitors (erlotinib, gefitinib, and afatinib), ALK inhibitors (crizotinib, ceritinib, and alectinib) and a ROS1 inhibitor (crizotinib) are clinically available for patients with advanced-stage lung cancer harboring the corresponding molecular alterations. The National Comprehensive Cancer Network guidelines for NSCLC recommend that all advanced lung cancers with an adenocarcinoma, large cell carcinoma, or NSCC, NOS morphology be tested for EGFR mutations and ALK rearrangements. Because the prevalence of ROS1 rearrangements in NSCLC is low (approximately 1.5%) and ROS1 rearrangements are mutually exclusive with other driver alterations, ROS1 should be tested only in patients with negative EGFR, ALK, and KRAS mutations or as part of broad molecular profiling. 3, 19 As for methods to detect these genetic alterations, EGFR testing consists of a variety of polymerase chain reaction-based assays, whereas fluorescence in situ hybridization (FISH) and immunohistochemistry are used for ALK rearrangements. 19 For ROS1 rearrangements, FISH is typically conducted, whereas immunohistochemistry may be used as a screening method with reflex to FISH for positive results. 20 Notably, the National Comprehensive Cancer Network NSCLC guideline panel strongly endorses broader molecular profiling (next-generation sequencing) with the goal of identifying rare driver mutations for which effective drugs may already be available in clinical trials (BRAF V600E mutation, highlevel MET amplifications or MET exon 14 skipping mutations, RET rearrangements, and HER2 mutations). 3 Recently, the blockade of the programmed death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) axis has emerged as a novel therapeutic strategy in NSCLC. The interaction of PD-1 with PD-L1 inhibits T-cell activation and allows tumor cells to bypass immune surveillance. Thus, PD-1/PD-L1 axis blockade may enhance an active immune response to the tumor. In fact, high-profile clinical trials have demonstrated impressive antitumor activity of PD-1/PD-L1 inhibitors in NSCLC. [21] [22] [23] [24] [25] In most analyses to date, increased PD-L1 expression by immunohistochemistry has been associated with higher overall response rates to PD-1/PD-L1 inhibitors, 21,23-25 although a specific combination of a PD-L1 antibody clone and an immunohistochemistry platform were used to predict the response to each PD-1 or PD-L1 inhibitor. 26 Subsequently, the PD-1 inhibitors nivolumab and pembrolizumab were granted US Food and Drug Administration approval for the treatment of patients with metastatic NSCLC, including both squamous cell carcinoma and adenocarcinoma, who progressed on or after platinum-based chemotherapy, and increased PD-L1 expression in the tumor needs to be confirmed by a companion diagnostic immunohistochemistry kit for the treatment with pembrolizumab. Cytology and small biopsy specimens from advanced cancer patients are important samples for predictive biomarker testing, which encompasses molecular assays and immunohistochemistry. For molecular assays, including polymerase chain reaction-based assays and FISH, both formalin-fixed, paraffin-embedded (FFPE) samples (biopsies and cell blocks) and cytology preparation (smears) can be used, but because cytology specimens are usually fixed in alcohol, they may be better for molecular testing than FFPE samples on account of the improved preservation of nuclear acids. In fact, several studies have shown the successful use of cytology specimens with as few as 100 tumor cells for next-generation sequencing. 27, 28 Notably, to facilitate molecular testing, sample adequacy needs to be ensured before samples are sent to molecular pathology laboratories. 29 Thus, it is recommended that the pathologist describe the cellularity and percentage of tumor and nontumor nucleated cells or the approximate number of tumor cells in the section as well as the presence or absence of necrosis and appropriate preservation and fixation. 5 The best preparation for immunocytochemistry appears to be FFPE tissue because antibodies are usually validated for FFPE specimens and the revalidation of each antibody is probably necessary when methanol-fixed samples are used. 19 In addition, PD-L1 immunohistochemistry using cytology specimens has not undergone extensive validation; thus, it is recommended that PD-L1 immunohistochemistry be performed on FFPE resection or biopsy samples. 19 Finally, in accordance with our growing understanding of the biology of lung cancer, the advancement of targeted therapy, and the identification of molecular alterations associated with resistance to targeted agents, it has become routine clinical practice to perform repeat FNA and/or biopsy with molecular testing at each point of clinical decision making. 30, 31 In this scenario, it is extremely important for the pathologist to be aware of the purpose of the submitted sample so that he or she can avoid tissue exhaustion due to an unnecessary immunohistochemistry evaluation and can direct the sample for the appropriate molecular testing.
CONCLUSION
In conclusion, because of the advancement of personalized medicine in lung cancer, the subtyping of NSCLC and predictive biomarker testing using FNA and biopsy specimens have never been more important. The pathologist needs to efficiently handle these small specimens, report the diagnosis/subtype in a clinically relevant format, and evaluate the tissue adequacy for molecular assays.
